Clinical Significance of<i>CDH13</i>Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

Objective: To investigate the clinical significance of protocadherin 17 (PCDH17) promoter methylation in bladder cancer. Methods: Methylation-specific polymerase chain reaction was used to examine the promoter methylation status of PCDH17 in tumour tissue specimens obtained from patients with bladder cancer, and in normal bladder epithelial tissue specimens obtained from age-and sex-matched controls. The correlations between methylation status and demographic and clinicopathological parameters, and disease outcome, were assessed. Results: Methylation of the PCDH17 promoter was detected in 77/115 (67.0%) patients with bladder cancer and 0/43 (0%) of the controls. Methylation was significantly associated with high cancer grade (G3), advanced cancer stage (T2-T4), large tumour diameter (> 3 cm) and tumour recurrence. Methylation was also associated with significantly shorter survival time compared with unmethylated PCDH17 in patients with bladder cancer, and was an independent predictor of overall survival. Conclusions: PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer.

Section: Discussionmentioning

confidence: 89%

Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma

Wang

Lin

Li³

et al. 2014

“…[21][22][23][24] DNA methylation can be detected in body fluids as well as tumour tissue, since double-stranded DNA fragments are present in the serum of patients with cancer, 9,11,25,26 and this DNA has a similar methylation status to that found in tumours. 4 Circulating tumour DNA may derive from tumour cells or result from DNA leakage caused by tumour necrosis or apoptosis. 9,20 The current study investigated the relationship between PCDH17 promoter methylation detected in serumderived DNA and clinicopathological characteristics and overall survival of patients with bladder cancer.…”

Section: Discussionmentioning

confidence: 99%

Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer

Luo

Li²,

Gui

et al. 2013

Objective: To investigate the prognostic value of protocadherin 17 (PCDH17) promoter methylation in serum-derived DNA of patients with bladder cancer. Methods: DNA was isolated from serum of patients with bladder cancer and from age-and sexmatched controls. Methylation-specific polymerase chain reaction was used to examine the methylation status of the PCDH17 promoter. The correlations between methylation status and clinicopathological characteristics and overall survival were examined. Results: PCDH17 promoter methylation was detected in 79/151 (52.3%) of patients with bladder cancer, and none of the 43 control subjects. Methylation was significantly associated with larger tumour diameter (>3 cm), high grade (G 3 ) and advanced stage (T 2 -T 4 ). Patients with PCDH17 promoter methylation had significantly shorter overall survival than those with unmethylated PCDH17 promoter. Methylation was an independent predictor of overall survival. Conclusions: PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. The detection of PCDH17 promoter methylation in serum-derived DNA may be a convenient and noninvasive predictive biomarker in routine clinical practice.

“…11 Changes in CDH13 gene expression have been reported to be associated with tumour behaviour in some human tumours. [11][12][13] Recent studies have highlighted the role of the CDH13 gene as a tumour suppressor in various human cancers such as lung cancer, bladder cancer, breast cancer and malignant melanoma. [11][12][13] The human CDH13 gene is mapped to 16q23.3 on chromosome 16, which is often inactivated by promoter methylation.…”

Section: Introductionmentioning

confidence: 99%

Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer

Wang

Lin

et al. 2014

Objective: To investigate the clinical significance of cadherin 13 (CDH13) gene promoter methylation in the serum of patients with prostate cancer. Methods: This prospective study examined the methylation status of CDH13 in serum samples obtained from patients with primary prostate cancer and age-matched control subjects, using methylation-specific polymerase chain reaction. Associations between methylation status of CDH13 and various clinicopathological features and patient survival were evaluated. Results: A total of 98 patients with prostate cancer and 47 control subjects were enrolled in the study. CDH13 promoter methylation was detected in 44 out of 98 (44.9%) patients with prostate cancer; no methylation was found in control subjects. Methylation of CDH13 was significantly associated with an increased Gleason score, an advanced tumour stage, and a high prostate-specific antigen level. CDH13 methylation was associated with a worse survival outcome and a relative risk of death of 6.132 (95% confidence interval: 3.160, 12.187). Conclusions: Promoter methylation of CDH13 occurred frequently in the serum of patients with prostate cancer, was associated with an increased risk of death, and may become a useful independent predictor of a poor prognosis.